Information Provided By:
Fly News Breaks for October 21, 2016
ALKS
Oct 21, 2016 | 05:34 EDT
Citi analyst Liav Abraham raised her price target for Alkermes to $62 saying last night's positive headline data for novel depression drug ALKS-5461 places the compound "firmly back into the Alkermes investment thesis." The analyst sees a 60% chance of the drug winning approval and has a peak revenue estimate of $1B on a non-risk-adjusted basis. Abraham keeps a Neutral rating on Alkermes citing "additional due diligence" on the drug.
News For ALKS From the Last 2 Days
There are no results for your query ALKS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.